You are currently browsing the archives for 11 September 2016.
Displaying 1 entry.

Adjuvant and immune response.

The plans for these two studies are already in our budget and guidance for the financial year 2004 and forth. The purpose of two parallel phase II trials is to generate as much information as possible about the relationship between dose, adjuvant and immune response.

Cooperation agreements are Schering-Plough, Lundbeck and Bavarian Nordic.. Jakob Schmidt Chief Executive Officer Additional information: Jakob Schmidt, Chief Executive Officer, telephone+45 4516 2525Note to editors: Pharmexa A / S is a leading company in the field of active immunotherapy for the treatment of severe chronic illnesses. Pharmexa AutoVac proprietary technology platform is broadly applicable, but the company has rheumatoid resources on a variety of cancers and chronic inflammatory diseases, with research and development programs for breast cancer, arthritis and bone degeneration targeted focus.